An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 137-145

  Wigal, Sharon B ^a   Raja, Pooja ^a   Shukla, Ankita ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention deficit hyperactivity disorder; Lisdexamfetamine; Prodrug

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; PLACEBO; UNCLASSIFIED DRUG; VENVANSE;

ABDOMINAL PAIN; ADVERSE OUTCOME; APPETITE; ATTENTION DEFICIT DISORDER; CLINICAL EFFECTIVENESS; COMORBIDITY; DATA BASE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL TRANSIT; HUMAN; IN VITRO STUDY; INCIDENCE; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRESCRIPTION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PH; SUCKING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINE PH;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DEXTROAMPHETAMINE; HUMANS; MIDDLE AGED; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871556928     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.754013     Document Type: Review

References (39)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision (DSM-IV-TR). Am Psychiatry Assoc; Washington, DC: 2000
2. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. Morb Mortal Wkly Rep 2010;59(44):1439-43
3. Pliszka SR. Practice Parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
4. FDA: Approval Letter. Drug Approval Package: Vyvanse (Lisdex-amfetamine dimesylate) NDA #021977. U.S. Food and Drug Administration. 2007.Available from: www.accessdata.fda. gov/drugsatfda-docs/nda/2007/021977s000TOC.cfm [Accessed 29 May 2009]
5. Stanczak A, Ferra A. Prodrugs and soft drugs. Pharmacol Rep 2006;58:599-613 (Pubitemid 44741679)
6. Da Prada M, Keller HH, Kettler PL, et al. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984;40:1165-72 (Pubitemid 15077826)
7. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite clopidogrel. Drug Metab Dispos 2002;30(11):1288-95 (Pubitemid 35265838)
8. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
9. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40(2):147-58 (Pubitemid 32111018)
10. Wigal SB, Maltas S, Crinella F, et al. Reading Performance as a Function of Treatment With Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed With ADHD. J Atten Disord 2012;16(1):23-33
11. Wigal SB, Wigal T, Schuck S, et al. Academic, behavioral and cognitive effects of OROS-methylphenidate on older children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21(2):121-31
12. Shaywitz S, Shaywitz B, Wietecha L, et al. Effect of atomoxetine on reading and phonological skills in children and adolescents with dyslexia or attention deficit/hyperactivity disorder and comorbid dyslexia. Poster presented at the 59th Annual Meeting of the American Academy of Child & Adolescent; October2012; San Francisco, CA
13. Shreeram S, He JP, Kalaydilian A, et al. Prevalence of enuresis and its association with attention-deficit/hyperactivity disorder among U.S. children: results from a nationally representative study. J Am Acad Child Adolesc Psychiatry 2009;48(1):35-41
14. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283(8):1025-30 (Pubitemid 30112216)
15. Zuvekas S, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012;169(2):160-6
16. Lahey BB, Pelham WE, Loney J, et al. Three-year predictive validity of DS-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age. Am J Psychiatry 2004;161(11):2014-20 (Pubitemid 39441401)
17. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-93 (Pubitemid 44665445)
18. Wigal SB, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007;17(2):153-64 (Pubitemid 46828911)
19. Wigal SB, Jun A, Wong AA, et al. Does prior exposure to stimulants in children with ADHD impact physiological effects from lisdexamfetamine dimesylate? Postgraduate Med 2010;122(5):27-34
20. Wigal SB, Wong AA, Jun A, et al. Adverse events in medication treatment-naive children with attention-Deficit/Hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol 2012;22(2):149-56
21. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 2007;34(3):1182-90 (Pubitemid 46394475)
22. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 2008;165(5):553-5 (Pubitemid 351705328)
23. Shire US, Inc. Vyvanse-(lisdexamfetamine dimesylate) C-II Prescribing Information. 2012. [Accessed June 2012
24. Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: a Review of its use in Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry 2010;19(4):303-14
25. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 2010;19(4):303-14
26. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 2009;31(1):142-76
27. Shire US, Inc. ADDERALL XR-Medication Guide. C-II. 2011. [Accessed June 2012
28. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48(3):293-302 (Pubitemid 351257766)
29. Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of LDX and Mixed amphetamine salts extended release in adults. Clin Pharmacol 2009;121(5):11-29
30. Vyanse(lisdexamfetamine dimesylate). Wayne, PA:Shire US Inc. 2008.Available from: http://www. vyvanse.comindexchild.aspWT. srch=1&src=1&mid=V000803& tid=1489731&KEYWORD= vyvanse&gelid-CIH-96fMvpcCFQO bFQodCXofS [Accessed 29 July 2012]
31. Krishnan SM, Stark JG. Multiple daily dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008;24:33-40 (Pubitemid 351160236)
32. Biederman J, Boellner SW, Childress A, et al. Lisexamfetamine dimesylate and mixed amphetamines salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6 (Pubitemid 47562371)
33. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdesamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double blind, forced dose, parallel group study. Clin Ther 2007;29:450-63
34. Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attentiondeficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010;6:34
35. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50:1001-11
36. Shire Canada Inc. Vyvanse-Product Monograph. Saint-Laurent, QC: Shire Canada Inc.; 2011
37. Subcommittee on Attention-Deficit/hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of Attention-Deficit/ hyperactivity Disorder in children and adolescents. Pediatrics 2011;128(5):1-16
38. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27
39. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006;10:92-111 (Pubitemid 44060289)